What are the outpatient criteria for prescribing sertraline for the first time?

Outpatient Criteria for First-Time Sertraline Prescription

Sertraline can be safely prescribed to adult outpatients with depression or anxiety disorders after confirming the diagnosis, screening for contraindications (particularly MAOI use within 14 days, QT prolongation risk, and seizure history), assessing suicide risk, and establishing a monitoring plan with follow-up within 1-2 weeks of initiation. 1, 2, 3

Pre-Prescription Assessment Requirements

Diagnostic Confirmation

• Depression: Must meet criteria for major depressive disorder with prominent depressed mood nearly every day for at least 2 weeks, plus at least 4 of 8 core symptoms (appetite/sleep changes, psychomotor changes, loss of interest, fatigue, guilt/worthlessness, concentration problems, suicidal ideation) 3
• Anxiety Disorders: FDA-approved for OCD, panic disorder, PTSD, social anxiety disorder, and PMDD 3
• Note: Sertraline may benefit patients with depressive symptoms not meeting full diagnostic criteria, including those with mild-to-moderate symptoms 4

Critical Safety Screening

Absolute Contraindications:

• Current or recent (within 14 days) MAOI use—risk of fatal serotonin syndrome 2
• Concurrent pimozide use 3

Relative Contraindications/Cautions:

• Seizure disorder history: Use cautiously as SSRIs can lower seizure threshold 2
• QT prolongation risk: While sertraline has lower QT risk than citalopram, screen for cardiac disease, electrolyte abnormalities, and concurrent QT-prolonging medications 2
• Bleeding risk: Particularly with concurrent NSAIDs or aspirin—SSRIs increase bleeding risk 2
• Bipolar disorder: Screen carefully as antidepressants can precipitate mania 2

Medication Interaction Review

• CYP2D6 substrates: Sertraline may interact with drugs metabolized by this pathway 2
• Other serotonergic drugs: Exercise caution combining with tramadol, triptans, other antidepressants, St. John's wort, or dextromethorphan 2
• Anticoagulants/antiplatelets: Document bleeding risk discussion 2

Suicide Risk Assessment and Monitoring Plan

All patients require baseline suicide risk evaluation given the FDA black box warning for increased suicidal thinking/behavior in patients under age 25 1, 2. The absolute risk increase is modest (0.7% risk difference, NNH=143) but mandates:

• Close monitoring beginning within 1-2 weeks of initiation 1
• Most intensive monitoring during first 1-2 months when suicide attempt risk is highest 1
• Watch for behavioral activation: Agitation, irritability, restlessness, or unusual behavior changes may signal worsening depression 1, 2
• Patient/family education: Provide clear instructions to report emergence of suicidal thoughts, agitation, or behavioral changes immediately 2

Dosing and Titration Strategy

Starting Dose

• Depression/OCD/PTSD/Social Anxiety: Start 25-50 mg daily 5, 6, 3
• Panic Disorder: Start 25 mg daily for first week, then increase to 50 mg 3
• Consider lower starting dose (even subtherapeutic "test dose") in patients prone to anxiety, as initial SSRI side effect can be increased anxiety/agitation 2

Titration Approach

• Conservative approach for mild-moderate presentations: Increase in smallest available increments at 1-2 week intervals for shorter half-life SSRIs like sertraline 2
• Faster titration may be appropriate for severe presentations, though higher doses don't necessarily correlate with better response and may increase adverse effects 2
• Typical therapeutic range: 50-200 mg daily 3
• Youth may require twice-daily dosing at lower sertraline doses 2

Follow-Up Schedule

Initial Phase (Weeks 1-8)

• First follow-up within 1-2 weeks: Assess tolerability, adherence, adverse effects, and suicide risk 1
• Regular monitoring: Continue frequent contact during first 6-8 weeks 1
• Response assessment at 6-8 weeks: If inadequate response, modify treatment (switch medications, augment, or add psychotherapy) 1

Continuation Phase

• Duration for first episode: Continue 4-9 months after satisfactory response 1
• Recurrent depression: Consider longer duration; patients with ≥2 episodes may benefit from extended therapy 1
• Periodic re-evaluation: Assess ongoing need for medication at regular intervals 1, 3

Patient Education Requirements

Inform patients about:

• Common side effects: Nausea, diarrhea, headache, insomnia/somnolence, sexual dysfunction, sweating 2
• Delayed onset of benefit: Clinical improvement typically begins around week 2, becomes clinically significant by week 6, with maximal benefit by week 12 or later 2
• Suicide risk monitoring: Importance of reporting worsening mood, suicidal thoughts, or behavioral changes 1, 2
• Discontinuation syndrome risk: Sertraline (shorter half-life) can cause withdrawal symptoms if stopped abruptly—requires gradual taper 2
• Pregnancy/breastfeeding: Sertraline transfers to breast milk in lower concentrations than other SSRIs, making it a preferred option 6, 7

Special Populations

Older Adults

• "Start low, go slow" approach 6
• Sertraline is a preferred agent in elderly patients alongside citalopram, escitalopram, mirtazapine, and venlafaxine 6

Pregnancy/Breastfeeding

• First-line options: Sertraline and escitalopram are recommended first-line agents for perinatal depression in treatment-naive patients 7
• Lower breast milk transfer: Sertraline and paroxetine have lower concentrations in breast milk 6

Common Pitfalls to Avoid

1. Starting too high: Begin with lower doses to minimize initial anxiety/agitation side effects 2
2. Inadequate monitoring: Missing the critical 1-2 week initial follow-up increases suicide risk 1
3. Premature discontinuation: Stopping before 6-8 weeks doesn't allow adequate trial duration 1
4. Abrupt cessation: Always taper to avoid discontinuation syndrome 2, 8
5. Missing drug interactions: Particularly MAOI combinations (absolute contraindication) and other serotonergic drugs 2
6. Inadequate patient education: Patients must understand delayed benefit, side effects, and warning signs requiring immediate contact 2